Home › Breast Cancer › Connecticut › Bridgeport
Breast Cancer clinical trials in Bridgeport, CT
21 studies for Breast Cancer are looking for participants at sites in and around Bridgeport (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Stony Brook University Medical Center, Stony Brook · 18 mi away
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RecruitingPhase 3
- Stony Brook University-Cancer Center ( Site 0034), Stony Brook · 18 mi away
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Stony Brook · 18 mi away
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RecruitingPhase 3
- Smilow Cancer Hospital Care Center - Trumbull, Trumbull · 4 mi away
- Smilow Cancer Hospital Care Center - Fairfield, Fairfield · 5 mi away
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Recruiting
- Stony Brook Cancer Center, Stony Brook · 18 mi away
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
RecruitingPhase 1/2
- Stony Brook University Hospital, Stony Brook · 18 mi away
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RecruitingPhase 3
- Stony Brook University Medical Center, Stony Brook · 18 mi away
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecruitingPhase 3
- Stony Brook University Cancer Center, Stony Brook · 18 mi away
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C. (Port Jefferson Station2), Port Jefferson Station · 19 mi away
- New York Cancer and Blood Specialists_North Shore Hematology Oncology Assocaites P.C.(Port Jefferson Station1), Port Jefferson Station · 19 mi away
- New York Cancers & Blood Specialists, Port Jefferson Station · 19 mi away
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecruitingPhase 3
- Hartford HealthCare - Saint Vincent's Medical Center, Bridgeport
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 mi away
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 mi away
- and 1 more
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
RecruitingPhase 2
- Stony Brook Cancer Center, Stony Brook · 18 mi away
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RecruitingPhase 2
- Smilow Cancer Hospital Care center at Trumbull, Trumbull · 4 mi away
- Smilow Cancer Hospital Care center at Fairfield, Fairfield · 5 mi away
FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
RecruitingPhase 1
- New York Cancer and Blood Specialists, Port Jefferson Station · 19 mi away
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecruitingPhase 3
- Stony Brook University Cancer Center, Stony Brook · 18 mi away
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RecruitingPhase 3
- Smilow Cancer Hospital - Fairfield, Fairfield · 5 mi away
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecruitingPhase 3
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull · 4 mi away
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield · 5 mi away
- Stony Brook University Medical Center, Stony Brook · 18 mi away
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
RecruitingObservational study
- Stony Brook Medicine, Stony Brook · 18 mi away
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
RecruitingEarly phase 1
- Stony Brook Breast Center, Stony Brook · 18 mi away
Definitive Radiation Therapy for Inoperable Breast Cancer
Recruiting
- Stony Brook University Cancer Center, Stony Brook · 18 mi away
Definitive Radiation for High-Risk Spine Metastases
RecruitingPhase 2
- Stony Brook University Hospital, Stony Brook · 18 mi away
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RecruitingObservational study
- Stony Brook University Cancer Center, Stony Brook · 18 mi away
About Breast Cancer
Breast cancer is a cancer that starts in the breast tissue, when cells change and grow out of control. These extra cells can form a mass called a tumor.
More about Breast Cancer on MedlinePlus
Breast Cancer trials in other cities
- New York City, NY136 studies
- Houston, TX126 studies
- Boston, MA112 studies
- Nashville, TN81 studies
- Los Angeles, CA73 studies
- Edison, NJ68 studies
- St. Louis, MO64 studies
- Queens, NY64 studies
- Durham, NC64 studies
- Chicago, IL59 studies
- Philadelphia, PA56 studies
- Dallas, TX55 studies
Other studies in Bridgeport
- Non-Small Cell Lung Cancer14 studies
- Lung Cancer13 studies
- Acute Myeloid Leukemia12 studies
- Cardiovascular Disease9 studies
- Cancer (all types)8 studies
- Head and Neck Squamous Cell Carcinoma8 studies
- Metastatic Cancer7 studies
- Heart Failure7 studies
- Brain Aneurysm6 studies
- Multiple Myeloma6 studies
- Prostate Cancer6 studies
- Ovarian Cancer5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.